Summary
One simple step to overall K+ control
Efficacy for all
Works from the 1st dose
Lowers serum K+ from the first dose, regardless of HK severity2
Sustained K+ Control
Proven to sustain K+ within normokalemia range over 52 weeks3
Proven efficacy in different patient profiles
Proven efficacy with concomitant RAASi use backed by 4 placebo-controlled trials across comorbidities,4–7 and in the real-world setting for haemodialysis patients8,9
Patient friendly
One sachet daily from the start
80–90% of patients need an 8.4 g sachet per day1,9
Odourless, taste-free
Proven in a palatability study to be a positive experience in terms of odour and taste9
Juice or soft food mixing options
Extra versatility to suit individual tastes1
Designed for tolerability
Na+ free exchange
Suitable for Na+ sensitive patients with no Na+ associated risk1
Minimal GI effects
Optimised physical characteristics to minimise undesirable GI effect1,10
References & footnotes
Abbreviations
GI, gastrointestinal; HK, hyperkalemia; K+, potassium; Na+, sodium; RAASi, renin-angiotensin-aldosterone-system inhibitor; SAEs, serious adverse events.
References
- Veltassa Gulf SmPC. Veltassa KSA SmPC.
- Di Palo KE, et al. Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting. JAMA Netw Open 2022;5(1):e2145236.
- Bakris GL, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease. JAMA 2015;314(2):151–61.
- Butler J, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur J Hear Fail 2022;43(41):4362–73.
- Weir MR, et al. Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med 2015;372(3):211–21.
- Agarwal R, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394(10208):1540–50.
- Pitt B, et al. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011;32:820–28.
- Kovesdy CP, et al. Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients. Kidney Int Rep 2019;4(2):301–9.
- Brenner M, et al. Palatability Profile of Patiromer, a Once-Daily Oral Potassium Binder for the Treatment of Hyperkalemia. American Society of Health System Pharmacists Annual Meeting. December 4–8, 2016. Las Vegas, NV. Poster, P4-075.
- Li L, et al. Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia. J Card Pharmacol Ther 2016;21(5):456–65.
GCC-PAT-2500019 | Date of preparation: October 2025